

## Press Release

### PBT up 21% to Rs. 157 Crores for the Quarter

**Vadodara, August 8<sup>th</sup>, 2024**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30<sup>th</sup> June, 2024.

#### Financial Highlights

##### For the Quarter

- Net Sales increased 5% to Rs.1562 crores.
- Net Profit up 12% to Rs.135 crores.
- EBITDA up 14% to Rs. 239 crores.

**Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said** "India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth.

The USFDA conducted an audit at our Formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18% during the quarter"

#### Operational Highlights

##### India Branded Business

- India Branded Business grew 9% to Rs. 572 crores for the quarter.
- Recorded robust growths in specialty therapies like Gynecology, Gastrointestinal, Anti Diabetic and Ophthalmology therapies and performed relatively better than the market in acute therapies.
- Excess heat waves in Q1 FY 25 lead to unnatural market disturbances in affected geographies.
- Animal Health business grew 23% for the quarter with basket of strong brands driving outperformance.
- New launches continue to do well along with promising future launches across key segments.

### International Business

- US Generics grew 18% to Rs. 461 crores for the quarter.
- 2 Launches in the US market during the quarter.
- Ex-US International Formulations grew 2% to Rs. 271 crores for the quarter.
- 206 Cumulative ANDA approvals.

### API Business

- API business at Rs. 259 crores for the quarter.

The summary of Total Revenue is as under:

(Rs in Crores)

| Particulars        | Q1 FY25     | Q1 FY24     | % Change  |
|--------------------|-------------|-------------|-----------|
| <b>Formulation</b> |             |             |           |
| India              | 572         | 524         | 9%        |
| USA                | 461         | 390         | 18%       |
| Ex- US             | 271         | 266         | 2%        |
| <b>API</b>         | 259         | 305         | (15%)     |
| <b>Total</b>       | <b>1562</b> | <b>1486</b> | <b>5%</b> |

### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Information about the company can be found at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com);  
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

### For more information contact:

**Ajay Kumar Desai**

**Phone: +91 022- 66953681 | 7045504460**

**Email: [ajay.desai@alembic.co.in](mailto:ajay.desai@alembic.co.in)**